 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Compugen Ltd.
 |
Compugen Ltd. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Novartis, Compugen, sign database agreement Aug 02 2001 05:59 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Proteins and genes are Compugen's favorite things. The firm develops technologies that are intended to improve the processes involved in genomics and proteomics (the study of genes and proteins, respectively). Its products include LEADS, a bioinformatics platform that assists in the analysis of genomic and protein data, and the Z3 system, which is designed to improve 2D gel analysis, a method for separating complex mixtures of proteins. Compugen's products are intended to enhance and expedite drug discovery efforts; the company is also commercializing the genes and proteins discovered in its own drug discovery division. Key customers include Eli Lilly, Merck, Pharmacia , and the National Institutes of Health.
COMPETITION |
 |
APBiotech Inc (dossier)
Applied Biosystems Group (ABI)
Clontech Laboratories, Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 6.90
1-Yr. Sales Growth: 115.6%
Employees: 130
Revenue per employee: $53,076.92
KEY PEOPLE |
 |
Mor Amitai
CEO
Nurit Benjamini
CFO
CONTACT INFO |
 |
72 Pinchas Rosen St.
Tel Aviv 69512, Israel
Phone: 972-376-8585
Fax: 972-376-8555
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |